Lymphocyte-rich Hodgkin lymphoma
- C81.4 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
- The 2025 edition of ICD-10-CM C81.4 became effective on October 1, 2024.
- This is the American ICD-10-CM version of C81.4 – other international versions of ICD-10 C81.4 may differ.
Applicable To
- Lymphocyte-rich classical Hodgkin lymphoma
Type 1 Excludes
- nodular lymphocyte predominant Hodgkin lymphoma (C81.0-)
The following code(s) above C81.4 contain annotation back-references
that may be applicable to C81.4:
- C00-D49 Neoplasms
- C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissue
- C81 Hodgkin lymphoma
Clinical Information
- A subtype of classical hodgkin lymphoma. Most patients present with peripheral lymphadenopathy and limited stage disease (stage i or ii). The survival and progression free survival are slightly better than in other subtypes of classical hodgkin lymphoma. (who, 2001)
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): Revised code
- New description: Lymphocyte-rich Hodgkin lymphoma
- 2016 description: Lymphocyte-rich classical Hodgkin lymphoma
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
- 2024 (effective 10/1/2023): No change
- 2025 (effective 10/1/2024): No change
Diagnosis Index entries containing back-references to C81.4:
- Lymphoma (of) (malignant) C85.90
- HodgkinC81.9-
- lymphocyte-rich C81.4- (classical)
- lymphocyte-rich classical C81.4-
- HodgkinC81.9-